Adocia Current Ratio 2016-2020 | ADOCY

Adocia current ratio from 2016 to 2020. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Adocia Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2020-12-31 $0.00B 0.00
2020-06-30 $0.05B $0.01B 3.75
2019-12-31 $0.06B $0.01B 4.65
2018-12-31 $0.07B $0.02B 4.11
2018-06-30 $0.09B $0.03B 3.12
2017-12-31 $0.05B $0.01B 5.04
2017-06-30 $0.07B $0.01B 6.42
2016-12-31 $0.08B $0.03B 2.50
2015-12-31 $0.10B $0.02B 4.22
2015-06-30 $0.09B $0.02B 4.63
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.083B $0.001B
Adocia SAS is a biotechnology company which is engaged in the development of insulin therapy. The Company develops a BioChaperone platform used for therapeutic protein delivery in regenerative medicine and chronic disease. Adocia SAS is based in Lyon, France.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76